High-Risk Myocardial Infarction Database Initiative
Studies
4
The primary objectives of this initiative were to use this large database to define more precisely the prognostic profile of this high risk population and to perform rigorous subset analyses.
The information has been extracted from the article:
Dickstein, Kenneth, Judith Bebchuk, and Janet Wittes. "The high-risk myocardial infarction database initiative." Progress in cardiovascular diseases 54.4 (2012): 362-366.
| Investigators | Contacts |
|---|---|
|
General Information
- Types of cohorts
-
- Clinical trial
- Region
- Australia, Eastern Europe, Israel, Latin America, North America, New Zealand, South Africa, South Korea, Taiwan, Western Europe .
- Setting
- International
- Funding
- The original budget for creating the common database was approximately US200,000. No public source was willing to provide funding, so individual members of the Scientific Committee made contributions from local research funds.
- Criteria of cohort's to be included
- Randomized, controlled, double-blind clinical trials that evaluated a pharmacologic intervention in highrisk patients following acute myocardial infarction complicated with signs of heart failure or evidence of left ventricular dysfunction.
- Health topic
-
- Cardiovascular diseases
- General epidemiology
- Socio-environmental context
-
- NA
Participants
Number of participants
- Total
- 28,771
- With harmonized data
- 28,771
Age range of the samples
- Minimum age
- 18
- Maximum age
- 150
Methodology for harmonization and integration
- Strategy of harmonization
- Ex-post
- Data processing methods
-
- NA
- Type of infrastructure
- NA
- Integrative data analysis
-
- Meta-analyses
- Pooled analyses
- Software
-
- R / Rmarkdown
- SAS
Number of cohorts
- Total
- 4
- With harmonized data
- 4
- Will more cohorts be harmonized?
- Number of harmonized variables (max.)
- 18
Access
- Availability of metadata
- Availability of individual data
- Under request
Individual Studies
| Acronym | Name | Study design | Participants | Countries |
|---|---|---|---|---|
| CAPRICORN | Cardvedilol Post Infarct Survival Control in Left Ventricular Dysfunction | Clinical trial | 1,959 | |
| EPHESUS | Eplerenone Post Acute Myocardial Infarction Heart Failure Efficacy and Survival Study | Clinical trial cohort | 6,632 | |
| OPTIMAAL | Optimal Trial in Myocardial Infarction with Angiotension II Antogonist, Losartan | Clinical trial cohort | 5,477 | |
| VALIANT | Valsartan in Acute Myocardial Infarction | Clinical trial cohort | 14,703 |